Our sample consisted of only DCIS patients, all uniformly treated according to the national guidelines that assure 5-year treatment of tamoxifen, regardless of menopausal status in women with hormone receptor-positive in situ disease. The gene discussed is NR4A1; the disease is ductal breast carcinoma in situ.